Caribou Biosciences released Q2 2026 revenue results alongside a strategy update, giving investors a fresh view of its financial position and year-end prioritie

Caribou Biosciences released Q2 2026 revenue results alongside a strategy update, giving investors a fresh view of its financial position and year-end priorities. The gene-editing company also pointed to ongoing pipeline progress, including vispa-cel data.